U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06959173) titled 'Organoid-guided Personalized Treatment of Pleural Effusion' on April 28.
Brief Summary: The study is a single-arm, single-center clinical research that utilizes patient-derived tumor organoids to predict drug sensitivity, thereby assisting clinicians in formulating treatment plans to benefit lung cancer patients with pleural effusion.
This study is divided into three parts: acquisition of clinical samples from patients, in vitro organoid culture and drug sensitivity testing, and correlation of organoid sensitivity results with clinical medication guidance. Researchers obtained pre-treatment tissue samples and provided them to Suzhou ...